We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$604M
1-Year Est. Return
96.57%
This Fund
S&P 500
This Quarter
Est. Return
+16.16%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$179M
AUM Growth
+$7.38M
(+4.3%)
Cap. Flow
+$20M
Cap. Flow
% of AUM
11.17%
Top 10 Holdings %
Top 10 Hldgs %
57.08%
Holding
70
New
27
Increased
8
Reduced
10
Closed
24
Avg Time Held Equity + Options
1.4
quarters
Top 10 Avg Time Held Equity + Options
1.5
quarters
Top 20 Avg Time Held Equity + Options
1.2
quarters
Avg Time Held Equity only
1.7
quarters
Top 10 Avg Time Held Equity only
1.6
quarters
Top 20 Avg Time Held Equity only
2.3
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sanofi
SNY
|
+$11.5M |
| 2 |
Biogen
BIIB
|
+$7.82M |
| 3 |
Puma Biotechnology
PBYI
|
+$5.84M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$4.59M |
| 5 |
GSK
GSK
|
+$3.28M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HRC
HILL-ROM HOLDINGS, INC.
HRC
|
+$5.98M |
| 2 |
Edwards Lifesciences
EW
|
+$5.15M |
| 3 |
Zimmer Biomet
ZBH
|
+$4.82M |
| 4 |
Aclaris Therapeutics
ACRS
|
+$3.76M |
| 5 |
NTUS
Natus Medical Inc
NTUS
|
+$3.16M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 66.2% |
| 2 | Miscellaneous | 27.33% |
| 3 | Industrials | 3.12% |
| 4 | Financials | 2.65% |
| 5 | Technology | 0.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
ACOR
1
PUT
DELISTED
Acorda Therapeutics
ACOR
| $22M | 12.28% |
+8,712
| New | +$25.1M |
2017 Q1
0 quarters
|
|
|
QTNT
2
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $16.3M | 9.14% |
58,452
+2,508
| +4% | +$640K |
2014 Q4
9 quarters
|
|
|
3
Sanofi
SNY
$93.7B
| $12.2M | 6.84% |
+270,422
| New | +$11.5M |
2017 Q1
0 quarters
|
|
|
4
GSK
GSK
$92.7B
| $11M | 6.17% |
209,210
+64,561
| +45% | +$3.28M |
2016 Q4
1 quarter
|
|
5
Philips
PHG
$24.3B
| $7.84M | 4.39% |
329,787
+46,842
| +17% | +$1.05M |
2016 Q1
4 quarters
|
|
|
6
Biogen
BIIB
$33.8B
| $7.56M | 4.23% |
+27,650
| New | +$7.82M |
2017 Q1
0 quarters
|
|
7
PUT
DELISTED
Sage Therapeutics
SAGE
| $7.31M | 4.09% |
+102,800
| New | +$6.02M |
2017 Q1
0 quarters
|
|
8
Rigel Pharmaceuticals
RIGL
$881M
| $6.25M | 3.5% |
188,818
+62,479
| +49% | +$1.59M |
2016 Q1
4 quarters
|
|
|
9
Puma Biotechnology
PBYI
$522M
| $5.95M | 3.33% |
+160,064
| New | +$5.84M |
2017 Q1
0 quarters
|
|
|
TRHC
10
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
| $5.58M | 3.12% |
414,045
+25,991
| +7% | +$373K |
2016 Q3
2 quarters
|
|
11
PUT
Merck
MRK
$350B
| $5.08M | 2.84% |
+83,840
| New | +$5.09M |
2017 Q1
0 quarters
|
|
12
Eli Lilly
LLY
$1.04T
| $4.86M | 2.72% |
57,786
-9,214
| -14% | -$738K |
2016 Q4
1 quarter
|
|
|
AET
13
DELISTED
Aetna Inc
AET
| $4.73M | 2.65% |
37,100
+17,100
| +86% | +$2.15M |
2016 Q4
1 quarter
|
|
14
Cardinal Health
CAH
$55.5B
| $4.73M | 2.64% |
57,950
-10,935
| -16% | -$861K |
2016 Q1
4 quarters
|
|
|
15
Thermo Fisher Scientific
TMO
$245B
| $4.61M | 2.58% |
+30,000
| New | +$4.59M |
2017 Q1
0 quarters
|
|
16
DELISTED
Advanced Accelerator Applications S.A.
AAAP
| $4.33M | 2.42% |
108,523
-44,809
| -29% | -$1.55M |
2015 Q4
5 quarters
|
|
|
DMK
17
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
| $3.75M | 2.1% |
12,612
-2,403
| -16% | -$606K |
2014 Q4
9 quarters
|
|
18
PUT
Johnson & Johnson
JNJ
$599B
| $3.74M | 2.09% |
+30,000
| New | +$3.58M |
2017 Q1
0 quarters
|
|
19
UnitedHealth
UNH
$339B
| $3.47M | 1.94% |
21,151
+4,964
| +31% | +$813K |
2016 Q3
2 quarters
|
|
20
PUT
Pfizer
PFE
$162B
| $3.42M | 1.91% |
+105,400
| New | +$3.32M |
2017 Q1
0 quarters
|
|
21
Medtronic
MDT
$119B
| $2.42M | 1.35% |
+30,000
| New | +$2.34M |
2017 Q1
0 quarters
|
|
22
Smith & Nephew
SNN
$11.7B
| $2.39M | 1.34% |
+77,244
| New | +$2.36M |
2017 Q1
0 quarters
|
|
23
CALL
Molina Healthcare
MOH
$10.9B
| $2.28M | 1.28% |
+50,000
| New | +$2.62M |
2017 Q1
0 quarters
|
|
24
Boston Scientific
BSX
$62.8B
| $2.24M | 1.25% |
90,000
-23,500
| -21% | -$571K |
2016 Q4
1 quarter
|
|
25
Teva Pharmaceutical Industries Limited
TEVA
$48.1B
| $2.23M | 1.25% |
+69,500
| New | +$2.37M |
2017 Q1
0 quarters
|
|
Similar funds
EFL
V
MAM
RCM
AMG
VV
VCP
EHI
Sio Capital Management's Q1 2017 Portfolio in Review
As of Q1 2017, Sio Capital Management held 70 positions worth $179M, up 4.3% from $171M the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Sio Capital Management deployed $20M of net new capital in Q1 2017, opening 27 new positions and adding to 8 existing holdings. Its largest new stake was Sanofi: 270,422 shares worth $12.2M.
By sector, the portfolio is most concentrated in Healthcare at 66% of assets, up from 51% a quarter earlier, followed by Miscellaneous and Industrials.
On the sell side, the largest reduction was Advanced Accelerator Applications S.A., an estimated $1.55M trimmed.
- Sio Capital Management's largest Q1 2017 buy was Sanofi: 270,422 shares worth $12.2M.
- Sio Capital Management added most to GSK in Q1 2017, an estimated $3.28M increase.
- Sio Capital Management's biggest Q1 2017 reduction was Advanced Accelerator Applications S.A., cutting an estimated $1.55M.
- Sio Capital Management fully exited HILL-ROM HOLDINGS, INC. in Q1 2017, selling an estimated $5.98M.
- Sio Capital Management's ten largest holdings make up 57% of its $179M portfolio in Q1 2017.
- Sio Capital Management opened 27 new positions and closed 24 in Q1 2017.
- Sio Capital Management's portfolio value rose 4.3% quarter-over-quarter to $179M.
Based on Sio Capital Management's 13F filing for Q1 2017, filed 15 May 2017.